Join

Compare · FTCH vs LOGC

FTCH vs LOGC

Side-by-side comparison of Farfetch Limited (FTCH) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FTCH and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
  • FTCH is the larger of the two at $7.25B, about 148.7x LOGC ($48.8M).
  • LOGC has hit the wire 9 times in the past 4 weeks while FTCH has been quiet.
  • FTCH has more recent analyst coverage (25 ratings vs 5 for LOGC).
MetricFTCHLOGC
Company
Farfetch Limited
ContextLogic Inc.
Price
$0.40-46.62%
$7.05+1.00%
Market cap
$7.25B
$48.8M
1M return
-
+0.00%
1Y return
-
+0.00%
Industry
Catalog/Specialty Distribution
Catalog/Specialty Distribution
Exchange
NYSE
NASDAQ
IPO
2018
2020
News (4w)
0
9
Recent ratings
25
5
FTCH

Farfetch Limited

Farfetch Limited, through its subsidiary, Farfetch.com Limited, provides an online marketplace for luxury fashion goods in the United States, the United Kingdom, and internationally. It operates through three segments: Digital Platform, Brand Platform, and In-Store. The company operates Farfetch.com, an online marketplace, as well as Farfetch app for retailers and brands. It also offers web design, build, development, and retail distribution solutions for retailers and brands. In addition, the company operates two Browns retail stores in London; two Stadium Goods retail store in New York and Chicago; and ten New Guards Off-White stores in Rome, Miami, Milan, New York, London, Paris, and Las Vegas, as well as two Ambush stores in Tokyo, and two Off-White outlets in Bicester and Serraville. Further, it operates approximately sixty New Guards franchised retail stores and four seasonal stores under various brands. Farfetch Limited was founded in 2007 and is headquartered in London, the United Kingdom.

LOGC

ContextLogic Inc.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.